Welcome to LookChem.com Sign In|Join Free
  • or
ethyl 7-bromo-[1,2,4]triazolo[1,5-a]pyridine-2-carboxylate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1380331-36-1

Post Buying Request

1380331-36-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1380331-36-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1380331-36-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,0,3,3 and 1 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1380331-36:
(9*1)+(8*3)+(7*8)+(6*0)+(5*3)+(4*3)+(3*1)+(2*3)+(1*6)=131
131 % 10 = 1
So 1380331-36-1 is a valid CAS Registry Number.

1380331-36-1Downstream Products

1380331-36-1Relevant academic research and scientific papers

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

-

Paragraph 000579, (2019/06/05)

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

-

Paragraph 1509; 1520; 1521; 1522, (2019/06/07)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

TRIAZOLOPYRIDINE COMPOUNDS

-

, (2012/06/16)

The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These

TRIAZOLOPYRIDINE COMPOUNDS

-

, (2012/06/30)

The invention is concerned with triazolopyridine compounds of formula (I), wherein R1, R2 , R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. The

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1380331-36-1